EUVIMEDSkopri EUVIMED
Open access

Pain associated with prostaglandin E 1 ‐containing intracavernosal injection medication is associated with poor erectile function recovery after radical prostatectomy

Michael West iD, Billy H Cordon, Yanira Ortega, Joseph Narus, John P Mulhall

Andrology · 2025

DOI: 10.1111/andr.13784 ↗

At a glance

Journal article in Andrology, 2025. Written by Michael West and 4 co-authors. Institution: Sexual and Reproductive Medicine Program, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Major MEDLINE topics: Prostatectomy, Alprostadil, Erectile Dysfunction, Penile Erection. Cited 4 times so far (Crossref); 40 references. The full text is freely available in PubMed Central. Funded by: National Institutes of Health/National Cancer Institute (NIH/NCI) with a Cancer Center Support Grant to Memorial Sloan Kettering Cancer Center, the Sidney Kimmel Center for Prostate and Urologic Cancers, and David H. Koch through the Prostate Cancer Foundation, NCI NIH HHS.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Intracavernosal injection therapy is often used as second‐line therapy for erectile dysfunction associated with radical prostatectomy when therapy with phosphodiesterase‐5 inhibitors has failed, but prostaglandin E1‐containing vasoactive agents are associated with penile pain in some men.

Objectives

To define the incidence of pain with prostaglandin E1‐containing intracavernosal injection mixtures for erectile dysfunction associated with radical prostatectomy when therapy with phosphodiesterase‐5 inhibitors has failed, and whether pain was a predictor of erectile function recovery. Materials and methods Men who underwent radical prostatectomy and were commenced on intracavernosal injection within 12 months of radical prostatectomy were included. A pain visual analog scale (0–10) was used to assess the degree of pain. Erectile function recovery was defined as the International Index of Erectile Function domain score ≥24 using phosphodiesterase‐5 inhibitors at 24 months.

Results

The study included 566 patients, mean age was 58 ± 14 (42–74) years. Duration post‐radical prostatectomy at intracavernosal injection training was 3.5 ± 3.5 m. Nerve sparing status: bilateral 76%, unilateral 13%, and non‐nerve sparing 11%. Incidence of pain with intracavernosal injection per nerve sparing status: bilateral 10% of patients, unilateral 32%, non‐nerve sparing 92% ( p < 0.001). Median visual analog scale in those experiencing pain: bilateral 4 (interquartile range 3, 5), unilateral 5.5 (interquartile range 3, 6), non‐nerve sparing 7 (interquartile range 3, 9) ( p < 0.001). Phosphodiesterase‐5 inhibitors success at 24 months (no pain vs. pain): bilateral 70% vs. 40% ( p < 0.001), unilateral 50% vs. 28% ( p < 0.001), non‐nerve sparing 10% vs. 0% ( p < 0.001). On multivariate analysis, predictors of failure to respond to phosphodiesterase‐5 inhibitors at 24 months post‐radical prostatectomy included baseline erectile function, increasing age, incomplete nerve‐sparing surgery, and presence of pain.

Discussion

The presence of penile pain with intracavernosal injection is associated with poorer erectile function recovery post‐radical prostatectomy.

Conclusions

Incidence of pain is high in men with non‐nerve sparing radical prostatectomy; older patient age, poorer nerve sparing, poor baseline erectile function, and the presence of penile pain with prostaglandin E1‐containing intracavernosal injection medication, were predictive of poor erectile function recovery using phosphodiesterase‐5 inhibitors at 24 months.

Subjects

MeSH terms (MEDLINE)

ProstatectomyAlprostadilErectile DysfunctionPenile ErectionPainVasodilator AgentsMaleHumansMiddle AgedAgedRecovery of FunctionAdultPhosphodiesterase 5 InhibitorsInjectionsPenis

Author keywords

PGE1intracavernosal injectionpainradical prostatectomy

Substances

AlprostadilPhosphodiesterase 5 InhibitorsVasodilator Agents

Authors and institutions

  • Sexual and Reproductive Medicine Program, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

ORCID profiles: Michael West

Funding

  • National Institutes of Health/National Cancer Institute (NIH/NCI) with a Cancer Center Support Grant to Memorial Sloan Kettering Cancer Center
  • the Sidney Kimmel Center for Prostate and Urologic Cancers, and David H. Koch through the Prostate Cancer Foundation
  • NCI NIH HHS
  • a SPORE grant in Prostate Cancer to Dr. H. Scher
  • Patient-Centered Outcomes Research Institute

Cite

APA

West, M., Cordon, B. H., Ortega, Y., Narus, J., & Mulhall, J. P. (2025). Pain associated with prostaglandin E 1 ‐containing intracavernosal injection medication is associated with poor erectile function recovery after radical prostatectomy. Andrology. https://doi.org/10.1111/andr.13784

Vancouver

West M, Cordon BH, Ortega Y, Narus J, Mulhall JP. Pain associated with prostaglandin E 1 ‐containing intracavernosal injection medication is associated with poor erectile function recovery after radical prostatectomy. Andrology. 2025. doi:10.1111/andr.13784

BibTeX
@article{West2025,
  author = {West, Michael and Cordon, Billy H and Ortega, Yanira and Narus, Joseph and Mulhall, John P},
  title = {Pain associated with prostaglandin E 1 ‐containing intracavernosal injection medication is associated with poor erectile function recovery after radical prostatectomy},
  journal = {Andrology},
  year = {2025},
  doi = {10.1111/andr.13784}
}
Start for free →